Home > Riviste > Minerva Obstetrics and Gynecology > Fascicoli precedenti > Articles online first > Minerva Obstetrics and Gynecology 2021 Apr 20

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Obstetrics and Gynecology 2021 Apr 20

DOI: 10.23736/S2724-606X.21.04752-7

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Oral administration of Lactobacillus crispatus M247 to papillomavirus-infected women: results of a preliminary, uncontrolled, open trial

Francesco DI PIERRO 1, 2 , Anna A. CRISCUOLO 3, Anna DEI GIUDICI 3, Roberto SENATORI 4, Francesco SESTI 3, Marco CIOTTI 3, Emilio PICCIONE 3

1 Scientific Department, Velleja Research, Milan, Italy; 2 Digestive Endoscopy Unit and Gastroenterology, Fondazione Poliambulanza, Brescia, Italy; 3 Section of Gynecology, Academic Department of Biomedicine and Prevention and Clinical Department of Surgery, Tor Vergata University Hospital, Rome, Italy; 4 SICPCV (Italian Society of Colposcopy and Cervico-Vaginal Pathology) board, Rome, Italy


PDF


BACKGROUND: Vaginal microbiotas can be clustered into five different possible categories (CST I to V), according to their bacterial dominance. In CST I, the dominance of Lactobacillus crispatus seems to correlate with better vaginal health and with a lower incidence of sine causa infertility, preterm delivery, bacterial vaginosis, and viral (including human papillomavirus; HPV) infection. According to the same method of classifying the vaginal microbiome, CST IV (non-Lactobacillusdominated) demonstrates a higher incidence of disorders.
METHODS: In an open, non-controlled study, we enrolled 35 HPV-positive women who mostly (N=24) demonstrated CST IV status, with the other individuals categorized as having either CST III (N=10) or CST II (N=1) microbiotas.
RESULTS: After 90 days of oral treatment with a probiotic (L. crispatus M247) we observed a reduction of approximately 70% in HPV positivity and a significant change in CST status with 94% of women now classified as CST I.
CONCLUSIONS: Despite the limitations of our study, it is the first demonstration that it is possible to intervene orally with an L. crispatus probiotic to bring about a change in CST status and, in parallel, increased HPV clearance.


KEY WORDS: HPV; CST; Vaginal microbiome; Cervical cancer; Microbiota analysis

inizio pagina